microRNA may help identify pancreatic cancer and possibly predict survival time
Preliminary research suggests that the expression pattern of microRNA may be useful in differentiating between chronic pancreatitis and pancreatic cancer and may be able to distinguish long and short term survival time for patients with pancreatic cancer.
Pancreatic cancer is a lethal disease, with the annual deaths nearly equaling the incidence of 33,000 in the United States.
In humans, aberrant expression of miRNAs contributes to carcinogenesis by promoting the expression of proto-oncogenes or by inhibiting the expression of tumor suppressor genes. MicroRNAs ( miRNAs ) are small non-coding RNAs. The role of miRNAs in ductal adenocarcinoma of the pancreas is not clear.
Mark Bloomston, of Ohio State University, Columbus, Ohio, and colleagues conducted a series of experiments to identify the pattern of miRNA expression in pancreatic adenocarcinoma to attempt to differentiate pancreatic cancer from benign pancreatic tissue and any differences in survival associated with certain miRNA expression.
Study specimens were obtained at a National Cancer Institute-designated Comprehensive Cancer Center from patients with ductal adenocarcinoma of the pancreas ( n = 65 ) or chronic pancreatitis ( n = 42 ) ( January 2000-December 2005 ).
RNA was harvested from resected pancreatic cancers and benign adjacent pancreatic tissue as well as from chronic pancreatitis specimens and subsequent miRNA was analyzed to identify associations with certain tissue types and prognosis.
" We have identified-we believe for the first time-a global expression pattern of miRNAs that can differentiate ductal adenocarcinomas of the pancreas from normal pancreas and chronic pancreatitis with 95 percent accuracy," the authors write. "A subgroup of 6 miRNAs was able to distinguish long-term survivors with node-positive disease from those dying within 24 months. Finally, high expression of miR-196a-2 was found to predict poor survival ( midpoint, 14.3 months vs. 26.5 months )."
" The present report contributes to the growing understanding of the role of miRNAs in oncogenesis and describes the global expression patterns of miRNAs in pancreatic adenocarcinoma. As we and other laboratories continue to identify the expression patterns of various solid tumors, the application of this knowledge may be broad. Such patterns may be able to be used to direct therapy in patients with metastatic tumors of unknown primary neoplasms or to help discriminate between benign and malignant neoplasms that would otherwise be indeterminate by routine histologic and immunohistochemical analysis. "
" More importantly, data such as ours, in which it is possible to begin to differentiate between patients with better or worse prognoses, may help guide the clinician when determining who should or should not receive aggressive therapy. Aside from these diagnostic and prognostic examples of how miRNA expression patterns can be used clinically, the ability of miRNAs to affect multiple genes in various pathways make them a logical target for investigation of novel antitumoral therapies. However, these preliminary data will first need to be validated in other studies," the authors write.
Source: Journal of American Medical Association, 2007
Mangafodipir, a contrast agent currently used in magnetic resonance imaging ( MRI ), may increase the cancer-killing ability of...
Researchers evaluate the effectiveness of a new antitumoral therapy by looking at how tumors respond to it. But in the...